Legacy Financial Advisors Inc. Increases Position in Corteva, Inc. $CTVA

Posted by Brian Himes on May 13th, 2026

Legacy Financial Advisors Inc. raised its position in Corteva, Inc. (NYSE:CTVA – Free Report) by 74.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,010 shares of the company’s stock after purchasing an additional 7,698 shares during the period. Legacy Financial Advisors Inc.’s holdings in Corteva were worth $1,207,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Corteva by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 80,536,951 shares of the company’s stock valued at $5,398,392,000 after buying an additional 317,538 shares during the last quarter. State Street Corp grew its position in shares of Corteva by 3.6% in the 3rd quarter. State Street Corp now owns 35,280,805 shares of the company’s stock valued at $2,386,041,000 after buying an additional 1,230,074 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Corteva by 5.9% in the 3rd quarter. Franklin Resources Inc. now owns 18,731,627 shares of the company’s stock valued at $1,266,820,000 after buying an additional 1,051,389 shares during the last quarter. Northern Trust Corp grew its position in shares of Corteva by 1.8% in the 3rd quarter. Northern Trust Corp now owns 11,169,284 shares of the company’s stock valued at $755,379,000 after buying an additional 194,728 shares during the last quarter. Finally, Legal & General Group Plc grew its position in shares of Corteva by 14.3% in the 3rd quarter. Legal & General Group Plc now owns 5,753,982 shares of the company’s stock valued at $389,142,000 after buying an additional 720,469 shares during the last quarter. 81.54% of the stock is owned by hedge funds and other institutional investors.

Corteva Stock Down 0.3%

CTVA stock opened at $82.59 on Wednesday. Corteva, Inc. has a one year low of $60.53 and a one year high of $85.63. The stock has a market capitalization of $55.24 billion, a PE ratio of 48.58, a price-to-earnings-growth ratio of 2.68 and a beta of 0.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.03 and a current ratio of 1.47. The company has a fifty day moving average of $80.88 and a 200-day moving average of $73.03.

Corteva (NYSE:CTVA – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The company had revenue of $4.91 billion during the quarter, compared to analysts’ expectations of $4.64 billion. During the same quarter last year, the business earned $1.13 EPS. The business’s revenue was up 11.0% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, analysts expect that Corteva, Inc. will post 3.7 EPS for the current year.

Corteva Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Monday, June 1st will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Monday, June 1st. Corteva’s dividend payout ratio (DPR) is 42.35%.

Insider Activity at Corteva

In related news, insider Brian Titus sold 8,311 shares of the firm’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the sale, the insider owned 8,090 shares in the company, valued at $619,289.50. This trade represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.15% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CTVA. Royal Bank Of Canada increased their target price on shares of Corteva from $95.00 to $97.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. UBS Group increased their target price on shares of Corteva from $88.00 to $90.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Oppenheimer increased their target price on shares of Corteva from $86.00 to $89.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. BNP Paribas Exane increased their target price on shares of Corteva from $74.00 to $77.00 in a research report on Wednesday, May 6th. Finally, Wolfe Research raised their price objective on shares of Corteva from $81.00 to $86.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Thirteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.52.

Read Our Latest Stock Analysis on CTVA

About Corteva

(Free Report)

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.